

DVT Summary Notes

In patients complaining of leg pain and/or swelling, evaluate the likelihood of DVT as investigation and treatment should differ according to risk

- **Only 10% of suspected cases end up being DVTs**
- Wells score
 - Three-tier form: low, moderate, high likelihood
 - Two-tier form: unlikely, likely
 - Used by Thrombosis Canada
 - 0 or one point: unlikely
 - 6% chance of DVT
 - Do a D-dimer
 - If positive->compressive ultrasound study
 - If negative-> focus on other differentials
 - 2+ points: likely
 - 28% chance of DVT
 - Do compressive ultrasound
 - If positive-> DVT
 - If negative-> do a D-dimer
 - If negative-> no DVT
 - If positive: repeat compressive ultrasound
 - Note: alternate diagnosis that is more or just as likely subtracts two points

Wells Score for DVT Diagnosis

CLINICAL FINDINGS	POINTS
Paralysis, paresis or recent orthopedic casting of lower extremity	1
Bedridden >3 days recently or major surgery within past 12 weeks	1
Localized tenderness of the deep veins	1
Swelling of entire leg	1
Calf swelling 3 cm greater than other leg (measured 10 cm below the tibial tuberosity)	1
Pitting edema greater in the symptomatic leg	1
Non-varicose collateral superficial veins	1
Active cancer or cancer treated within 6 months	1
Previously documented DVT	1
Alternative diagnosis at least as likely as DVT (Baker's cyst, cellulitis, muscle damage, superficial vein thrombosis, post-thrombotic syndrome, inguinal lymphadenopathy, extrinsic venous compression)	-2

In patients with high probability for thrombotic disease (e.g. extensive leg clot, suspected pulmonary embolism), start anticoagulant therapy if tests will be delayed

- If compressive ultrasound takes more than 4 hours, should start anticoagulation for any patients likely of having DVT
- Anticoagulants to use:
 - DOAC
 - Easy and convenient
 - LMWH bridging to Warfarin
 - Cheaper

Identify patients likely to benefit from DVT prophylaxis

Hospitalized Medical Patients

- Risk factors
 - Age >70
 - Previous VTE
 - Immobility for 3+ days
 - Stroke
 - Acute spinal cord injury
 - Active cancer
 - Known thrombophilia
 - Sepsis
 - Acute inflammatory conditions
 - Acute infectious disease
 - Obesity (BMI>30)
 - Hormone therapy
 - ICU admission
 - Cardiac or respiratory failure
- Balance with risk of bleeding
 - Active gastroduodenal ulcer
 - Previous bleed in past 3 months
 - Advanced age
 - Severe renal failure (<30mL/min)
 - Hepatic failure
 - Active cancer
 - Platelet count <50 x10⁹/L

Non-orthopaedic surgical patients

- For average bleed risk: start prophylaxis within 12 hours of completion of surgery for most elective non-orthopaedic surgical patients for whom thromboprophylaxis is indicated
- For higher risk of VTE: thromboprophylaxis should be continued at least until discharge from hospital for up to 30 days in select patients

Utilize Investigations for DVT allowing for their limitations

Physical exam

- Not always the most accurate!

D-dimer

- Sensitive but not specific
- Many things can increase D-dimer
 - Some examples
 - Inflammatory disease
 - Cancer
 - Pregnancy
 - Recent surgery
 - Hospitalization
 - Trauma
 - Older age
- D-dimers are great for ruling out a VTE but not so great at ruling in

Compressive ultrasound

- In lower limb, use popliteal and femoral veins
- Can try to identify clot and also try to collapse the vein
 - Normal veins should collapse easily
- Note: selective area
 - If there is still clinical suspicion of DVT should get a D-dimer
 - If positive: repeat study in 5-7 days or request whole leg study

Consider the possibility of an underlying coagulopathy in patients with DVT, especially when unexpected

- Provoking causes
 - Venous trauma
 - Immobility
 - Physiologic causes
- Unprovoked
 - Refer to hematologist or thrombosis clinic

In patients with DVT, use oral anticoagulation appropriately

Class	Notes	Dosing												
<u>DOAC</u>	<ul style="list-style-type: none"> -Easy to administer -No lab monitoring -Lower risk of bleeding -Some are used as monotherapy, others need a course of LMWH prior to initiation -Caution with renal function less than 30mL/min -Contraindicated in pregnancy 	<p>Abixiban (Eliquis)</p> <ul style="list-style-type: none"> • 10mg PO BID 7 days and then 5 mg PO BID for rest of treatment period <p>Rivaroxabon (Xarelto)</p> <ul style="list-style-type: none"> • 15 mg PO BID 21 days and then 20mg PO once daily for rest of treatment period 												
<u>LMWH</u>	<ul style="list-style-type: none"> -Monotherapy -Good for patients with active cancer and those who are pregnant -Education on self injection needed -Most often used in conjunction with Warfarin for at least the first five days, until the INR is ≥ 2 for two consecutive days -Caution with renal function less than 30mL/min 	<p>Tinzaparin</p> <ul style="list-style-type: none"> • 175 units/kg SC daily <p>Enoxaparin</p> <ul style="list-style-type: none"> • 1.5mg/kg SC daily or 1mg/kg BID <p>Dalteparin</p> <ul style="list-style-type: none"> • 200 units/kg SC daily • 100 units/kg SC BID for patients over 100 kg 												
<u>Unfractionated Heparin</u>	<ul style="list-style-type: none"> -Only used in specific cases 1. Patients with severe renal insufficiency 2. Patients with high bleed risk 3. Patients who develop DVT shortly after receiving thrombolytic therapy 	<p>IV</p> <ul style="list-style-type: none"> • IV bolus 5000 units or 80 units/kg • Then infusion of 18-20 units/kg/hour • Targeting an aPTT or antiXa level per hospital policy <p>Subcutaneous</p> <ul style="list-style-type: none"> • 333units/kg initially • Then 250 units/kg BID • Note: does not require aPTT monitoring/targeting 												
<u>Warfarin</u>	<ul style="list-style-type: none"> -Requires concurrent treatment with LMWH to bridge (usually at least 5 days) 	<p>Warfarin</p> <p>5 mg/once daily initially</p> <p>2-3 mg/day if elderly, frail or low body weight</p> <p>7.5-10 mg/day if young, healthy or larger</p> <p>INR before 4th dose</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>INR</th> <th>Dose</th> </tr> </thead> <tbody> <tr> <td>>1.5</td> <td>Increase from 5 mg to 7.5-10 mg/daily and check again in 2-3 days</td> </tr> <tr> <td>1.5-1.9</td> <td>Continue 5 mg/day and check again in 2-3 days</td> </tr> <tr> <td>2-3</td> <td>Drop to 2.5 mg daily and check again in 2-3 days</td> </tr> <tr> <td>3.1-4</td> <td>Drop to 1.25 mg daily and check in 2-3 days</td> </tr> <tr> <td>>4</td> <td>Hold until INR <3</td> </tr> </tbody> </table>	INR	Dose	>1.5	Increase from 5 mg to 7.5-10 mg/daily and check again in 2-3 days	1.5-1.9	Continue 5 mg/day and check again in 2-3 days	2-3	Drop to 2.5 mg daily and check again in 2-3 days	3.1-4	Drop to 1.25 mg daily and check in 2-3 days	>4	Hold until INR <3
INR	Dose													
>1.5	Increase from 5 mg to 7.5-10 mg/daily and check again in 2-3 days													
1.5-1.9	Continue 5 mg/day and check again in 2-3 days													
2-3	Drop to 2.5 mg daily and check again in 2-3 days													
3.1-4	Drop to 1.25 mg daily and check in 2-3 days													
>4	Hold until INR <3													